ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Portland, OR, USA:

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Portland, Oregon, United States and 164 other locations

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Iomab-B
Drug: Conventional Care

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Portland, Oregon, United States and 23 other locations

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML hav...

Enrolling
Acute Myeloid Leukemia (AML)
FLT3-mutated Acute Myeloid Leukemia
Drug: Azacitidine
Drug: Venetoclax

Phase 1, Phase 2

Astellas
Astellas

Portland, Oregon, United States and 18 other locations

the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML....

Active, not recruiting
Acute Myeloid Leukemia
Biological: WU-NK-101

Phase 1

Wugen, Inc.

Portland, Oregon, United States and 8 other locations

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differen...

Active, not recruiting
AML With Monocytic Differentiation
CMML
Biological: IO-202 and Azacitidine + Venetoclax
Biological: IO-202

Phase 1

Immune-Onc Therapeutics

Portland, Oregon, United States and 13 other locations

\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Fludarabine

Phase 3

LLS PedAL Initiative, LLC

Portland, Oregon, United States and 73 other locations

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Portland, Oregon, United States and 160 other locations

standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits ...

Enrolling
Acute Myeloid Leukemia
Procedure: Bone Marrow Aspirate
Drug: Cytarabine

Phase 1

OHSU Knight Cancer Institute
OHSU Knight Cancer Institute

Portland, Oregon, United States

combination with all-trans retinoic acid (ATRA) in participants with acute myeloid leukemia (AML) who have relaps...

Active, not recruiting
Acute Myeloid Leukemia
Drug: TAS1440
Drug: TAS1440 + ATRA

Phase 1

Taiho Pharma
Taiho Pharma

Portland, Oregon, United States and 7 other locations

This phase I trial tests the safety, side effects, and best dose of entrectinib when given with ASTX727 in treating patients with acute myeloid...

Enrolling
Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Drug: Entrectinib
Drug: Decitabine and Cedazuridine

Phase 1

OHSU Knight Cancer Institute
OHSU Knight Cancer Institute

Portland, Oregon, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems